HELIXBIND Marlborough, MA, USA
HelixBind’s proprietary RaPID platform provides culture-free characterization of pathogens and their resistance mechanisms directly from patient specimens. With CARB-X’s support, HelixBind will accelerate the testing in a clinical setting of RaPID/BSI, an assay to diagnose bloodstream infections associated with sepsis, a global health priority. Effective management requires timely diagnosis, but current practices often take days for results. RaPID/BSI will provide the information clinicians need sooner, helping to save lives, reduce hospitalizations stays, and improve antimicrobial stewardship.
Current Development Stage: System Integration and Testing
CARB-X Investment: Initial investment of up to $1m with potential option payments up to $1m.
Initial CARB-X Investment Date: March 1, 2018
Graduation Date: April 15, 2022